Linn Energy LLC Outlook Revised To Positive From Stable; Ratings Affirmed

  • ID: 1784404
  • May 2011
  • Standard & Poors
1 of 3

U.S. energy exploration and production company Linn Energy continues to expand liquids production and reserves. We expect average debt leverage to improve, and distribution coverage should improve. We affirmed our 'B+' corporate credit rating on the company and assigned a 'B' issue rating to the proposed senior unsecured notes. We revised the outlook to positive to reflect the potential for an upgrade in the next year if Linn can maintain debt leverage of 3.5x or less. NEW YORK (Standard & Poor's) May 10, 2011--Standard & Poor's Ratings Services said today it affirmed its 'B+' corporate credit rating on Linn Energy LLC and revised the outlook to positive from stable. At the same time we assigned a 'B' rating to Linn's...

Companies mentioned in this report are: Linn Energy LLC,Linn Energy Finance Corp.
Action: Affirmed
Action: Outlook: Positive

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Linn Energy LLC,Linn Energy Finance Corp.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.